Welcome to our dedicated news page for Poseida Therapeutics (Ticker: PSTX), a resource for investors and traders seeking the latest updates and insights on Poseida Therapeutics .
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Poseida Therapeutics 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Poseida Therapeutics 's position in the market.
Rhea-AI Summary
Poseida Therapeutics, Inc. (Nasdaq: PSTX) announced early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor (CAR)-T therapy candidate. The study showed a 100% objective response rate in patients who were not previously treated with a BCMA-targeted bispecific T cell-engaging antibody. The program also presented favorable emerging safety and reliability profile. The company is also advancing its cell and gene therapy programs and platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Poseida Therapeutics, Inc. (PSTX) announces progress in allogeneic programs, acceleration of Roche Collaboration milestones, and a $50 million strategic investment from Astellas Pharma. Acceptance of three poster presentations at ASH Annual Meeting also announced.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
-
Rhea-AI Summary
Poseida Therapeutics, Inc. (Nasdaq: PSTX) will be participating in the Stifel 2023 Healthcare Conference on November 14, 2023, and the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023. The webcasts will be available on the Investors & Media Section of Poseida's website, with a replay available for approximately 90 days following the presentation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
Rhea-AI Summary
Poseida Therapeutics, Inc. (Nasdaq: PSTX) has announced the acceptance of three poster presentations at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. The presentations will focus on cell and gene therapy treatments for cancer and rare diseases. The company will present early safety results of P-BCMA-ALLO1, a CAR-T therapy for patients with relapsed/refractory multiple myeloma. They will also present a tumor-bearing murine xenograft model as a bioassay for assessing CAR-T product potency. Additionally, they will discuss effective gene therapy for hemophilia A using a novel non-viral formulation. A fourth abstract on the editing efficiency of the in vivo Cas-CLOVER™ Site-Specific Gene Editing System will be published in the ASH journal Blood.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.31%
Tags
-
Rhea-AI Summary
Mark Gergen appointed as Executive Chairman of the Board of Directors of Poseida; Kristin Yarema, Ph.D., to become President and CEO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
-
Rhea-AI Summary
Poseida Therapeutics to participate in investor conferences in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.36%
Tags
Rhea-AI Summary
Poseida Therapeutics announces financial results for Q2 2023, with revenues of $20.0 million and a net loss of $27.5 million. Cash position as of June 30, 2023, is $214.6 million, expected to fund operations into early 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
37.88%
Tags
-
Rhea-AI Summary
Poseida Therapeutics receives $50 million strategic investment from Astellas, extending cash runway guidance and implementing enhancements to allogeneic programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.47%
Tags
-
Rhea-AI Summary
Astellas Pharma will invest $50 million in Poseida Therapeutics, acquiring approximately 8.8% of the company. Astellas will also have exclusive negotiation rights for licensing Poseida's allogeneic CAR-T cell therapy product candidate for solid tumors. The investment aligns with Astellas' focus on immuno-oncology and its commitment to developing next-generation cancer drugs. Poseida is dedicated to advancing cancer cell therapy and gene therapy using genetic engineering technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.63%
Tags
Rhea-AI Summary
Poseida Therapeutics has received FDA clearance for its Investigational New Drug application for P-CD19CD20-ALLO1, an allogeneic dual CAR-T cell therapy targeting CD19 and CD20 antigens. This therapy is being developed in partnership with Roche and aims to treat relapsed or refractory B-cell malignancies. The clearance marks the first known FDA IND clearance for an allogeneic dual CAR-T therapy targeting CD19 and CD20.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
Poseida Therapeutics, Inc.
Nasdaq:PSTX
PSTX Rankings
PSTX Stock Data
223.85M
54.57M
34.52%
47.58%
4.27%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
United States of America
SAN DIEGO
About PSTX
poseida therapeutics, inc. is currently developing car-t and gene therapy products for cancer and orphan diseases. spinout of transposagen biopharmaceuticals early this year, poseida is also collaborating with j&j’s janssen to develop allogeneic car-t therapies against cancer. poseida boasts best-in-class genome engineering capabilities for effectively silencing target genes or inserting therapeutic genes and/or technologies. proprietary tools include piggybac™ dna modification system, nextgen™ crispr, xtn™ talen and footprint-free™ gene editing system, which are clean (synthetic and virus-free) and can be surgically precise. poseida aims to shuttle the first car-t and gene therapy product candidates into phase i clinical trials in early 2016. poseida is now hiring and searching for ambitious and motivated scientists desiring a fast-paced work environment with diverse research opportunities in the field of cellular and gene therapy.